{"filing":{"accession_number":"0001213900-26-072299","cik":"0001536196","ticker":"CANF","company_name":"Can-Fite BioPharma Ltd.","form":"6-K","filing_date":"2026-06-26","report_date":null,"primary_document":"ea0295976-6k_canfite.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1536196/000121390026072299/ea0295976-6k_canfite.htm"},"events":[{"id":14105,"run_id":12543,"accession_number":"0001213900-26-072299","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The press release announces the allowance of a Japanese patent (JP 2025-049941) covering Namodenoson's use for fat loss and obesity treatment. This is a material intellectual property milestone that strengthens the company's global patent portfolio in a major pharmaceutical market and supports future partnering opportunities for a lead drug candidate in a rapidly expanding $60+ billion obesity therapeutics market. While not a discrete event type like M\u0026A or exec change, it is a significant operational/strategic development affecting the company's competitive positioning and asset value.","company_name":"Can-Fite BioPharma Ltd.","ticker":"CANF","filing_date":"2026-06-26","form":"6-K","submitted_at":null,"items":[{"id":11440,"accession_number":"0001213900-26-072299","item_number":"EX-99.1","item_title":"ea029597601ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The press release announces the allowance of a Japanese patent (JP 2025-049941) covering Namodenoson's use for fat loss and obesity treatment. This is a material intellectual property milestone that strengthens the company's global patent portfolio in a major pharmaceutical market and supports future partnering opportunities for a lead drug candidate in a rapidly expanding $60+ billion obesity therapeutics market. While not a discrete event type like M\u0026A or exec change, it is a significant operational/strategic development affecting the company's competitive positioning and asset value.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-26T11:10:38.255507+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11440,"accession_number":"0001213900-26-072299","item_number":"EX-99.1","item_title":"ea029597601ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The press release announces the allowance of a Japanese patent (JP 2025-049941) covering Namodenoson's use for fat loss and obesity treatment. This is a material intellectual property milestone that strengthens the company's global patent portfolio in a major pharmaceutical market and supports future partnering opportunities for a lead drug candidate in a rapidly expanding $60+ billion obesity therapeutics market. While not a discrete event type like M\u0026A or exec change, it is a significant operational/strategic development affecting the company's competitive positioning and asset value.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-26T11:10:38.255507+00:00","company_name":"Can-Fite BioPharma Ltd.","ticker":"CANF","filing_date":"2026-06-26"}]}